
    no patients were enrolled
  
['melanoma']
['cobimetinib', 'vemurafenib']

        Inclusion Criteria:

          -  Signed informed consent

          -  Signed HIV testing consent

          -  Life expectancy ≥ 12 weeks

          -  Able to swallow pills

          -  ECOG performance status 2 or less

          -  Adequate bone marrow function

          -  Adequate renal function

          -  Adequate liver function

          -  Negative urine pregnancy test within 7 days prior to commencement of dosing in
             premenopausal women

          -  Histological diagnosis of unresectable AJCC stage III or stage IV, BRAFV600E/K mutant
             melanoma

          -  Measurable disease

          -  Accessible tumor that can be biopsied

          -  Naive to targeted therapy (Prior immune-based therapy in the adjuvant setting or for
             advanced disease will be allowed if >2 weeks from study entry)

        Exclusion Criteria:

          -  Active systemic infection

          -  Active autoimmune disease or history of known or suspected autoimmune disease

          -  Active brain metastases or leptomeningeal metastases

          -  Treatment with any immunomodulatory medication within 4 weeks of initiation of study
             therapy.

          -  Positive test for hepatitis B virus

          -  Positive test for hepatitis C virus

          -  Positive test for human immunodeficiency virus (HIV)

          -  Pregnant, lactating or breast feeding women

          -  Localized radiation therapy within the last 14 days

          -  History of malabsorption

          -  No consumption of the following within 7 days prior to start of treatment:

               -  St. John's wort or hyperforin (potent cytochrome P450 CYP3A4 enzyme inducer)

               -  Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor

          -  History or evidence of cardiovascular risk

          -  History or evidence of retinal pathology
      